By Staff Reporter Gilead Sciences has come under fire after announcing a secretive deal to supply its long-acting injectable HIV prevention drug, lenacapavir (LEN-LA), to the Global Fund to Fight AIDS, Tuberculosis and Malaria. The agreement—shrouded in indefinite price secrecy—has been widely condemned by civil society organisations, health advocates, and global health experts who warn it undermines transparency, accountability, and equitable access. The Global Fund, financed by public money, has invited nine African countries—South Africa, Eswatini, Lesotho, Mozambique, Kenya, Uganda, Zambia, Zimbabwe, and Nigeria—to participate in the agreement. However, the…
Read MoreGilead’s Secrecy Over HIV Prevention Shot Sparks Global Outrage
